Sec Form 13G Filing - Medine GmbH filing for - 2026-05-15

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
X0202 SCHEDULE 13G/A 0002056296-25-000003 0002123975 XXXXXXXX LIVE 6 Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) 03/31/2026 0001776985 BioNTech SE 09075V102 An der Goldgrube 12 Mainz 2M 55131 Medine GmbH 2M 0.00 39218111.00 0.00 39111390.00 39218111.00 N 15.5 OO Item 9: Consists of 39,111,390 ordinary shares held by Medine GmbH and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares. Ugur Sahin W8 858209.00 39218111.00 858209.00 39111390.00 40076320.00 N 15.8 IN Item 6: Consists of 39,111,390 ordinary shares held by Medine GmbH, 858,209 ordinary shares held by Prof. Ugur Sahin, M.D., and 106,721 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares. BioNTech SE An der Goldgrube 12, Mainz, Germany, 55131 This Amendment No. 6 to Schedule 13G is being jointly filed by Medine GmbH and Prof. Ugur Sahin, M.D., each of the foregoing, a "Reporting Person," and together, the "Reporting Persons". The Reporting Persons have entered into a Joint Filing Agreement, dated February 13, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 13, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is Philipp-von-Zabern-Platz 1, D-55116 Mainz, Germany. Medine GmbH is a German limited liability company (Gesellschaft mit beschrankter Haftung). Prof. Ugur Sahin, M.D. is a citizen of Turkey. Y See the responses to Item 9 on the attached cover pages. See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026. See the responses to Item 5 on the attached cover pages. See the responses to Item 6 on the attached cover pages. See the responses to Item 7 on the attached cover pages. See the responses to Item 8 on the attached cover pages. Y N N See responses to Item 2(a) and Item 4. N See responses to Item 2(a) and Item 4. Y Y Y Medine GmbH /s/ Prof. Ugur Sahin, M.D. Prof. Ugur Sahin, M.D./Authorized Signatory 05/15/2026 Ugur Sahin /s/ Prof. Ugur Sahin, M.D. Prof. Ugur Sahin, M.D. 05/15/2026 primary_doc.xml